Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Dolorès Carballo"'
Autor:
Cristina B. Guzman, Vincent Woo, S.J. Weisnagel, Xiaotian M. Zhang, Sheetal Pradhan, Gregg Gerety, George Tsoukas, Shuyu Zhang, Claude A. Piché, Elizabeth R. Seaquist, James R. Conway, Rémi Rabasa-Lhoret, Hélène Dulude, Dolorès Carballo
Publikováno v:
Diabetes, Obesity & Metabolism
In the present multicentre, open-label, prospective, phase III study, we evaluated the real-world effectiveness and ease of use of nasal glucagon (NG) in the treatment of moderate/severe hypoglycaemic events (HEs) in adults with type 1 diabetes (T1D)
Autor:
Maryam Tafreshi, Emmanouil Rampakakis, Myriam Triest, Marianne Rufiange, Aziz A. Sadoune, Shuyu Zhang, Hélène Dulude, Claude A. Piché, Eric Sicard, Cristina B. Guzman, Michelle Xiaotian Zhang, Dolorès Carballo
Publikováno v:
Diabetes, Obesity & Metabolism
Aims Nasal glucagon (NG) is a nasally-administered glucagon powder, absorbed through the nasal mucosa, designed for treatment of severe hypoglycaemia. This study evaluated the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of NG in otherwise
Autor:
Dolorès Carballo, Cristina B. Guzman, Adam Shames, Martin Lafontaine, Jean-François Yale, Rebecca Margolies, Shuyu Zhang, Michelle Xiaotian Zhang, Hélène Dulude, Claude A. Piché, Marc Egeth, Nicole Kaplowitz, Emily Dissinger
Publikováno v:
Diabetes Technology & Therapeutics
Background: During severe hypoglycemic episodes, people with diabetes depend on others to help with treatment. We compared needle-free nasal glucagon and commercially available injectable glucagon for ease of use by caregivers of people with diabetes
Autor:
Myriam Triest, David J Esdaile, Claude A. Piché, Morten Bendix Jensen, Magdolna Török-Bathó, C Nicholas Edwards, Dolorès Carballo, Frederick E. Reno
Publikováno v:
Cutaneous and ocular toxicology. 35(3)
The intranasal route is a promising route of administration for several emergency rescue drugs including naloxone and glucagon. Glucagon nasal powder (GNP) is a novel, needle-free delivery system for intranasal administration of glucagon for the trea
Autor:
Dolorès Carballo, Sherwin Silo, Patricia Stotland, Myriam Triest, Kevin McInally, Patrick Normand, Frederick E. Reno, Claude A. Piché
Publikováno v:
BMC Pharmacology & Toxicology
Background Glucagon nasal powder (GNP), a novel intranasal formulation of glucagon being developed to treat insulin-induced severe hypoglycemia, contains synthetic glucagon (10 % w/w), beta-cyclodextrin, and dodecylphosphocholine. The safety of this